Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer

Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer

Abstract Background Immune checkpoint inhibitors (ICIs) are an established treatment for non‐small cell lung cancer (NSCLC) that have demonstrated durable clinical benefits (DCBs). Previous studies have suggested NY‐ESO‐1 and LAG‐3 to be surrogate markers of ICI responses in NSCLC; therefore, we exp...

Full description

Bibliographic Details
Main Authors: Eun Hee Jung, Hee Ryeong Jang, Se Hyun Kim, Koung Jin Suh, Yu Jung Kim, Ju‐Hyun Lee, Jin‐Haeng Chung, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong‐Wan Kim, Dae Seog Heo, Jong Seok Lee
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Thoracic Cancer
Subjects:
immune checkpoint inhibitor
LAG‐3
non‐small cell lung cancer
NY‐ESO‐1
PD‐L1
Online Access:https://doi.org/10.1111/1759-7714.13834

Internet

https://doi.org/10.1111/1759-7714.13834

Similar Items